Literature DB >> 2275214

Design of toxicokinetic studies.

D A Smith1, M J Humphrey, C Charuel.   

Abstract

1. Toxicokinetics is defined as pharmacokinetic studies in animals during actual toxicity studies or under conditions mimicking them (species, duration, dose level, etc.). 2. Toxicology studies require toxicokinetics to check whether systemic exposure reflects administered dose. In particular, it is important to know whether the absence of toxicity at a given dose is due to the innocuousness of the compound or to its poor bioavailability. 3. Pivotal toxicology studies may require different toxicokinetic support than that of early studies, as more is learned of the compound and its metabolites. Considerations need to be placed on such factors as the choice of biological matrix for drug assay, the relevance of metabolites, and which dose levels require the most pharmacokinetic investigation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2275214     DOI: 10.3109/00498259009046838

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  6 in total

1.  Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies.

Authors:  E I Ette; C A Howie; A W Kelman; B Whiting
Journal:  Pharm Res       Date:  1995-05       Impact factor: 4.200

Review 2.  Integration of animal pharmacokinetic and pharmacodynamic data in drug safety assessment.

Authors:  D A Smith
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

Review 3.  Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responses.

Authors:  A Monro
Journal:  J Pharmacokinet Biopharm       Date:  1994-02

Review 4.  The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development.

Authors:  D K Walker
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

Review 5.  Design of drugs through a consideration of drug metabolism and pharmacokinetics.

Authors:  D A Smith
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Jul-Sep       Impact factor: 2.441

6.  Pharmacokinetic Profile of Kaurenoic Acid after Oral Administration of Araliae Continentalis Radix Extract Powder to Humans.

Authors:  Eun-Jeong Choi; Go-Wun Choi; Seung-Jeong Yang; Yong-Bok Lee; Hea-Young Cho
Journal:  Pharmaceutics       Date:  2018-12-01       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.